Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review

Table 5

Phase 2 clinical trials of sorafenib in colorectal cancer.

Study	Status	Results	NCT identifier
Sorafenib versus placebo + FOLFOX or FOLFORI in the second-line treatment of colorectal cancer	Recruiting	Pending	NCT00889343
Sorafenib + capecitabine in patients with pretreated advanced CRC	Recruiting	Pending	NCT01290926
BAY 43-9006 plus cetuximab to treat colorectal cancer	Recruiting	Pending	NCT00326495
Sorafenib + FOLFORI in CRC after failure of oxaliplatin therapy	Recruiting	Pending	NCT00839111
Sorafenib + capecitabine in previously treated CRC	Recruiting	Pending	NCT01471353
Sorafenib + irinotecan in metastatic CRC and KRAS mutation	Completed	Pending	NCT00989469
Sorafenib, cetuximab, and irinotecan in treating patients with mCRC	Ongoing, not recruiting	Pending	NCT00134069
Sorafenib and bevacizumab versus single agent bevacizumab	Ongoing, not recruiting	Pending	NCT00826540
External-Beam radiation therapy, capecitabine, and sorafenib in treating patients with locally advanced rectal cancer	Recruiting	Pending	NCT00869570